KRYS Overview
Upcoming Projects (KRYS)
-
Don’t see a project related to the company you care about? Create your own!
Executed Projects (KRYS)
-
A second look: Discussing Vyjuvek uptake in patients with dystrophic epidermolysis bullosa (DEB)
Ticker: KRYS
Executed On: Feb 01, 2024 at 04:00 PM EST -
Discussing Vyjuvek uptake in patients with dystrophic epidermolysis bullosa (DEB)
Ticker: KRYS
Executed On: Jan 23, 2024 at 06:00 PM EST -
A discussion of EB-101 from Abeona Therapeutics as a potential autologous cell therapy in recessive dystrophic epidermolysis bullosa (RDEB)
Tickers: ABEO, KRYS, BBIO
Executed On: Oct 26, 2022 at 08:30 PM EDT -
A Second Look: Examining the potential of Krystal's B-VEC in treating dystrophic epidermolysis bullosa (DEB) after FDA granted Priority Review designation
Ticker: KRYS
Executed On: Sep 08, 2022 at 06:30 PM EDT -
Examining the potential of Krystal's B-VEC in treating dystrophic epidermolysis bullosa (DEB) after FDA granted Priority Review designation
Ticker: KRYS
Executed On: Sep 07, 2022 at 01:15 PM EDT
Upcoming & Overdue Catalysts (KRYS)
-
Don’t see a catalyst related to the company you care about? Create your own!
Occurred Catalysts (KRYS)
-
Krystal Biotech (KRYS) Announces Topline Results from GEM-3 Pivotal Trial of VYJUVEK in Patients with Dystrophic Epidermolysis Bullosa
Ticker: KRYS
Occurred on: Nov 29, 2021
Strategic Initiatives (KRYS)
-
Don’t see a strategic initiative related to the company you care about? Create your own!
